Position
Compound Planning, Inc. in BridgeBio Pharma, Inc.
Back to the book · All holders of BBIO
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$6.07K$76.49 → $74.26
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 2.72K | $208.3K | — | — | — | 0.0% |
| Q1 2026 | 2.74K | $203.4K | $74.26 | −$6.07K | $1.19K | 0.0% |